Filing Flows › Dogwood Therapeutics (DWTX) › Q3 2026
Dogwood Therapeutics (DWTX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 6, 2026
Dogwood Therapeutics (DWTX) reported revenue of $100K for the third quarter 2026 (Q3 2026).
Revenue$100K
Year over year—
Quarter over quarter—
Operating margin—
Net earnings−$4.9M
Dogwood Therapeutics, Q3 2026: revenue $100K, net loss $4.9M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $100K | — | — |
| Operating profit | −$4.9M | — | — |
| Net earnings | −$4.9M | — | — |
| Operating cash flow | −$4.6M | — | — |
What changed
Revenue was $100K in Q3 2026.
Gross margin was 11.9%. Operating costs exceeded revenue by $4.9M, an operating margin of -4917.3%. The quarter ended with a net loss of $4.9M.
Operating cash flow was −$4.6M. Non-cash charges added back $558K of share-based compensation. Working capital and other items used $312K.
Questions
What was Dogwood Therapeutics' revenue in the third quarter 2026?
Dogwood Therapeutics (DWTX) reported revenue of $100K for the third quarter 2026 (Q3 2026).